A Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SHR7390 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 02 Jun 2017
At a glance
- Drugs SHR 7390 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 24 May 2017 Status changed from not yet recruiting to recruiting.
- 23 Nov 2016 New trial record